- Home
- EOI vs CMRX Comparison
EOI vs CMRX Comparison
Compare EOI & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- CMRX
- Stock Information
- Founded
- EOI 2004
- CMRX 2000
- Country
- EOI United States
- CMRX United States
- Employees
- EOI N/A
- CMRX N/A
- Industry
- EOI Finance/Investors Services
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- EOI Finance
- CMRX Health Care
- Exchange
- EOI Nasdaq
- CMRX Nasdaq
- Market Cap
- EOI 827.9M
- CMRX 797.3M
- IPO Year
- EOI N/A
- CMRX 2013
- Fundamental
- Price
- EOI $18.98
- CMRX $8.52
- Analyst Decision
- EOI
- CMRX Hold
- Analyst Count
- EOI 0
- CMRX 4
- Target Price
- EOI N/A
- CMRX $8.51
- AVG Volume (30 Days)
- EOI 83.6K
- CMRX 8.5M
- Earning Date
- EOI 01-01-0001
- CMRX 03-21-2025
- Dividend Yield
- EOI 7.19%
- CMRX N/A
- EPS Growth
- EOI N/A
- CMRX N/A
- EPS
- EOI N/A
- CMRX N/A
- Revenue
- EOI N/A
- CMRX $212,000.00
- Revenue This Year
- EOI N/A
- CMRX $2,685.38
- Revenue Next Year
- EOI N/A
- CMRX $1,050.23
- P/E Ratio
- EOI N/A
- CMRX N/A
- Revenue Growth
- EOI N/A
- CMRX N/A
- 52 Week Low
- EOI $14.36
- CMRX $0.75
- 52 Week High
- EOI $18.88
- CMRX $8.53
- Technical
- Relative Strength Index (RSI)
- EOI 40.68
- CMRX 83.28
- Support Level
- EOI $18.31
- CMRX $8.41
- Resistance Level
- EOI $19.68
- CMRX $8.52
- Average True Range (ATR)
- EOI 0.32
- CMRX 0.02
- MACD
- EOI 0.03
- CMRX -0.15
- Stochastic Oscillator
- EOI 48.78
- CMRX 85.72
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.